Nervous System Disorders

Category: Neurology, HIC#13853
Title:
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease Who are Apolipoprotein E 4 Non-Carriers (DSG001)
Contact:Paula Damgaard
Phone:(434)243-5420
E-mail:pld5c@virginia.edu

UVa Health System, Department of Neurology Memory Disorders Clinic seeks Women and Men ages 50 years and older with a diagnosis of Probable Alzheimers Disease for research study.

The purpose of the study is to assess whether an experimental drug called Dimebon is safe, well tolerated and effective for use in subjects in Alzheimers disease compared to a placebo (a drug with no active ingredient).
Study involves taking an experimental medicine/placebo, blood draws, MRIs of the head, ECGs, physicals, and memory testing. There are 10 visits over 52 weeks, each visit lasting approximately 1-4 hours.

Study-related provided free of charge.
Compensation for study visits completed is a $50 gift card.

Contact Information:
For more information please contact:
" Paula Damgaard, RN
" 434-243-5420/ pld5c@virgnia.edu
" Insert IRB-HSR # 13853

Principal Investigator: David Geldmacher, MD
Primary Investigator: Geldmacher David, S
Department: Neurology
 Accepts adult enrollment :YES
Accepts minor enrollment :NO